1. A p53-dependent translational program directs tissue-selective phenotypes in a model of ribosomopathies.
- Author
-
Tiu GC, Kerr CH, Forester CM, Krishnarao PS, Rosenblatt HD, Raj N, Lantz TC, Zhulyn O, Bowen ME, Shokat L, Attardi LD, Ruggero D, and Barna M
- Subjects
- Adaptor Proteins, Signal Transducing genetics, Animals, Body Patterning, Cell Cycle Proteins genetics, Gene Expression Regulation, Developmental, Mice, Mice, Knockout, Phenotype, Ribosomes metabolism, Adaptor Proteins, Signal Transducing metabolism, Cell Cycle Proteins metabolism, Extremities embryology, Haploinsufficiency, Protein Biosynthesis, Protein Processing, Post-Translational, Ribosomal Proteins physiology, Tumor Suppressor Protein p53 physiology
- Abstract
In ribosomopathies, perturbed expression of ribosome components leads to tissue-specific phenotypes. What accounts for such tissue-selective manifestations as a result of mutations in the ribosome, a ubiquitous cellular machine, has remained a mystery. Combining mouse genetics and in vivo ribosome profiling, we observe limb-patterning phenotypes in ribosomal protein (RP) haploinsufficient embryos, and we uncover selective translational changes of transcripts that controlling limb development. Surprisingly, both loss of p53, which is activated by RP haploinsufficiency, and augmented protein synthesis rescue these phenotypes. These findings are explained by the finding that p53 functions as a master regulator of protein synthesis, at least in part, through transcriptional activation of 4E-BP1. 4E-BP1, a key translational regulator, in turn, facilitates selective changes in the translatome downstream of p53, and this thereby explains how RP haploinsufficiency may elicit specificity to gene expression. These results provide an integrative model to help understand how in vivo tissue-specific phenotypes emerge in ribosomopathies., Competing Interests: Declaration of interests D.R. is a shareholder of eFFECTOR Therapeutics and a member of its scientific advisory board., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF